Lupus & antiphospholipid syndrome
Systemic Lupus Erythematosus Disease Activity Score Remission and Low Disease Activity States Discriminate Drug From Placebo and Better Health‐Related Quality of Life
Authors' conclusion
SLE-DAS remission and LDA showed discriminant ability for identifying patients receiving active drug in SLE clinical trials. Attainment of these SLE-DAS targets are associated with better HR-QoL.
Study context
- Population
- Patients with SLE in the pooled BLISS-52 and BLISS-76 trials
- Comparison
- Belimumab 1 mg/kg and 10 mg/kg vs placebo
- Primary endpoint
- SLE-DAS remission and LDA attainment and discrimination between belimumab and placebo
- Follow-up
- 52 weeks
Methodological detailspost hoc analysis, pooled data
- Post hoc analysis
- Pooled data
Primary result
As reported in the abstract
SLE-DAS LDA attainment · week 52
Odds ratio
1.459
P = 0.023
Belimumab 1 mg/kg · RR 1.377; NNT 20.4
Odds ratio
1.853
P < 0.001
Belimumab 10 mg/kg · RR 1.668; NNT 11.5
Further findings
| Outcome | Belimumab 10 mg/kg | Placebo | OR for attaining SLE-DAS remission | P value |
|---|---|---|---|---|
| SLE-DAS remission attainment · week 52Belimumab 10 mg/kg vs Placebo · RR for attaining SLE-DAS remission 1.454; NNT 21.7 | 14.7% | 10.1% | 1.532 | P = 0.019 |
HR-QoL (SF-36 domain and summary scores; Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F)) in Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) remission and low disease activity (LDA) attainers vs non-attainers · week 52
- Higher SF-36 domain and summary scores in patients attaining SLE-DAS remission and LDA
- all P < 0.001
- Higher FACIT-F scores in patients attaining SLE-DAS remission and LDA
- both P < 0.001
- Mean improvements from baseline in SF-36 and FACIT-F scores significantly higher in patients achieving SLE-DAS remission and LDA
Original publication
Systemic Lupus Erythematosus Disease Activity Score Remission and Low Disease Activity States Discriminate Drug From Placebo and Better Health‐Related Quality of Life. Arthritis Care Res (Hoboken). Published 29 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →